Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition

It is estimated that ~50% of patients with melanoma harbour B-Raf (BRAF)V600 driver mutations, with the most common of these being BRAFV600E, which leads to the activation of mitogen-activated protein kinase proliferative and survival pathways. BRAF inhibitors are used extensively to treat BRAF-muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowdo, Florencia Paula Madorsky, Barón, Antonela, Gallagher, Stuart John, Hersey, Peter, Emran, Abdullah Al, Von Euw, Erika M., Barrio, María Marcela, Mordoh, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170042/
https://www.ncbi.nlm.nih.gov/pubmed/32236593
http://dx.doi.org/10.3892/ijo.2020.5031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170042/
https://www.ncbi.nlm.nih.gov/pubmed/32236593
http://dx.doi.org/10.3892/ijo.2020.5031

Ejemplares similares